CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Active:	Yes
Cancer Type:	Non-Hodgkin Lymphoma	NCT ID:	NCT04637763
Trial Phases:	Phase I	Protocol IDs:	CB10A (primary) NCI-2021-04061
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Caribou Biosciences, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04637763

Summary

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and
immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma
after lymphodepletion consisting of cyclophosphamide and fludarabine.

Objectives

This clinical trial is a first-in-human, Phase 1, multicenter, open-label evaluation of
safety and emerging efficacy of CB-010 in adults with relapsed/refractory B cell
non-Hodgkin lymphoma. The study is conducted in two parts: Part A is dose escalation
following a 3 + 3 design, with sequential, prespecified, increasing doses. Part B is the
expansion portion where patients will receive CB-010 at the dose determined in Part A.

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.